lanifibranor
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
Mechanism of action
- pan-PPAR agonist
- attenuates progression of fibrosis in non-alcoholic steatohepatitis
More general terms
References
- ↑ Francque SM, Bedossa P, Ratziu V et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 2021 Oct 21; 385:1547. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34670042 https://www.nejm.org/doi/10.1056/NEJMoa2036205